Combination Products: FDA Releases Guidance on CGMP Requirements
FDA has released the long-awaited final guidance Current Good Manufacturing Practice Requirements for Combination Products. Although the rule doesn’t set forth any new requirements, it explains which CGMP requirements apply when a combination product is being manufactured to create a “transparent and streamlined regulatory framework for firms to use when demonstrating compliance with applicable CGMP requirements,” according to the document.
The guidance also defines combination product, provides an overview of the rule, explains the role of the FDA centers related to any combination product CGMP matters, and gives hypothetical examples to show companies how to comply with the requirements.
Related Articles
-
FDA releases achievements of its Combination Product Review Program, along with next steps for the near term.
-
Some key factors that companies should not overlook when developing drug-device products.
-
The agency is creating a virtual center of excellence to expedite the development of combination products.
-
Combination products are a major growth area for life science companies and in the future, many companies have or will have combination products in their portfolio. Combination products are made of drug, device and/or biologics constituent parts. Each constituent part…
-
The agency calls out specific devices that should include human factors data in premarket submissions, along with recommendations for combination products.
